EG BioMed has been closely collaborating with the Health Management Center of Shuang Ho Hospital. During a recent key meeting, Director Dr. Shih-Yu Ko and Deputy Director Dr. Chen enthusiastically praised and endorsed the early detection technology for pancreatic, colorectal, and lung cancers developed by EG BioMed. This groundbreaking technology, which achieves 90%-99% sensitivity, specificity, and accuracy through blood tests, has generated significant excitement. Dr. Ko and Dr. Chen are confident that this innovation will inject powerful new momentum into global health management and has the potential to revolutionize cancer screening. They have pledged their strong support for the continued development of this product, holding high expectations for its future success and emphasizing that both parties are committed to creating a new era in health management together.